Skip to Main content Skip to Navigation
Journal articles

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00484825
Contributor : Philippe Saas <>
Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM
Last modification on : Tuesday, October 27, 2020 - 2:35:52 PM

Links full text

Identifiers

Collections

Citation

Arlene Chan, D. W. Miles, Xavier Pivot. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.. Annals of Oncology, Elsevier, 2010, 21 (12), pp.2305-15. ⟨10.1093/annonc/mdq122⟩. ⟨inserm-00484825⟩

Share

Metrics

Record views

163